<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
<journal-id journal-id-type="publisher-id">CAM4</journal-id>
<journal-title-group>
<journal-title>Cancer Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2045-7634</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29168353</article-id>
<article-id pub-id-type="pmc">5773952</article-id>
<article-id pub-id-type="doi">10.1002/cam4.1256</article-id>
<article-id pub-id-type="publisher-id">CAM41256</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Cancer Prevention</subject>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm</article-title>
<alt-title alt-title-type="left-running-head">R. E. Reinbolt et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="cam41256-cr-0001">
<name>
<surname>Reinbolt</surname>
<given-names>Raquel E.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1250-2222</contrib-id>
<address>
<email>raquel.reinbolt@osumc.edu</email>
</address>
<xref ref-type="aff" rid="cam41256-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0002">
<name>
<surname>Sonis</surname>
<given-names>Stephen</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cam41256-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0003">
<name>
<surname>Timmers</surname>
<given-names>Cynthia D.</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0004">
<name>
<surname>Fernández‐Martínez</surname>
<given-names>Juan Luis</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cam41256-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0005">
<name>
<surname>Cernea</surname>
<given-names>Ana</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cam41256-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0006">
<name>
<surname>de Andrés‐Galiana</surname>
<given-names>Enrique J.</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cam41256-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0007">
<name>
<surname>Hashemi</surname>
<given-names>Sepehr</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="cam41256-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0008">
<name>
<surname>Miller</surname>
<given-names>Karin</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0009">
<name>
<surname>Pilarski</surname>
<given-names>Robert</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cam41256-cr-0010">
<name>
<surname>Lustberg</surname>
<given-names>Maryam B.</given-names>
</name>
<xref ref-type="aff" rid="cam41256-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="cam41256-aff-0001">
<label><sup>1</sup></label>
<institution>The Ohio State University Comprehensive Cancer Center</institution>
<named-content content-type="city">Columbus</named-content>
<named-content content-type="country-part">Ohio</named-content>
</aff>
<aff id="cam41256-aff-0002">
<label><sup>2</sup></label>
<institution>Primary Endpoint Solutions</institution>
<named-content content-type="city">Watertown</named-content>
<named-content content-type="country-part">Massachusetts</named-content>
</aff>
<aff id="cam41256-aff-0003">
<label><sup>3</sup></label>
<institution>Brigham and Women's Hospital and the Dana‐Farber Cancer Institute</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">Massachusetts</named-content>
</aff>
<aff id="cam41256-aff-0004">
<label><sup>4</sup></label>
<institution>University of Oviedo</institution>
<named-content content-type="city">Oviedo</named-content>
<country country="ES">Spain</country>
</aff>
<aff id="cam41256-aff-0005">
<label><sup>5</sup></label>
<institution>Harvard School of Dental Medicine</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">Massachusetts</named-content>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Raquel Reinbolt, 320 W 10th Avenue, B407 Starling‐Loving Hall, Columbus, Ohio 43210. Tel: 614 366 8541; Fax: 6142934372; E‐mail: <email>raquel.reinbolt@osumc.edu</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>1</month>
<year>2018</year>
</pub-date>
<volume>7</volume>
<issue>1</issue>
<issue-id pub-id-type="doi">10.1002/cam4.2018.7.issue-1</issue-id>
<fpage>240</fpage>
<lpage>253</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>05</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 Published by John Wiley & Sons Ltd. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:CAM4-7-240.pdf" xlink:type="simple"></self-uri>
<abstract id="cam41256-abs-0001">
<title>Abstract</title>
<p>Many breast cancer (<styled-content style="fixed-case">BC</styled-content>) patients treated with aromatase inhibitors (<styled-content style="fixed-case">AI</styled-content>s) develop aromatase inhibitor‐related arthralgia (<styled-content style="fixed-case">AIA</styled-content>). Candidate gene studies to identify <styled-content style="fixed-case">AIA</styled-content> risk are limited in scope. We evaluated the potential of a novel analytic algorithm (<styled-content style="fixed-case">NAA</styled-content>) to predict <styled-content style="fixed-case">AIA</styled-content> using germline single nucleotide polymorphisms (<styled-content style="fixed-case">SNP</styled-content>) data obtained before treatment initiation<bold>.</bold> Systematic chart review of 700 <styled-content style="fixed-case">AI</styled-content>‐treated patients with stage I‐<styled-content style="fixed-case">III BC</styled-content> identified asymptomatic patients (<italic>n</italic> = 39) and those with clinically significant <styled-content style="fixed-case">AIA</styled-content> resulting in <styled-content style="fixed-case">AI</styled-content> termination or therapy switch (<italic>n</italic> = 123). Germline <styled-content style="fixed-case">DNA</styled-content> was obtained and <styled-content style="fixed-case">SNP</styled-content> genotyping performed using the Affymetrix <styled-content style="fixed-case">UK</styled-content> BioBank Axiom Array to yield 695,277 <styled-content style="fixed-case">SNP</styled-content>s. <styled-content style="fixed-case">SNP</styled-content> clusters that most closely defined <styled-content style="fixed-case">AIA</styled-content> risk were discovered using an <styled-content style="fixed-case">NAA</styled-content> that sequentially combined statistical filtering and a machine‐learning algorithm. <styled-content style="fixed-case">NCBI</styled-content> PhenGenI and Ensemble databases defined gene attribution of the most discriminating <styled-content style="fixed-case">SNP</styled-content>s. Phenotype, pathway, and ontologic analyses assessed functional and mechanistic validity. Demographics were similar in cases and controls. A cluster of 70 <styled-content style="fixed-case">SNP</styled-content>s, correlating to 57 genes, was identified. This <styled-content style="fixed-case">SNP</styled-content> group predicted <styled-content style="fixed-case">AIA</styled-content> occurrence with a maximum accuracy of 75.93%. Strong associations with arthralgia, breast cancer, and estrogen phenotypes were seen in 19/57 genes (33%) and were functionally consistent. Using a <styled-content style="fixed-case">NAA</styled-content>, we identified a 70 <styled-content style="fixed-case">SNP</styled-content> cluster that predicted <styled-content style="fixed-case">AIA</styled-content> risk with fair accuracy. Phenotype, functional, and pathway analysis of attributed genes was consistent with clinical phenotypes. This study is the first to link a specific <styled-content style="fixed-case">SNP</styled-content>/gene cluster to <styled-content style="fixed-case">AIA</styled-content> risk independent of candidate gene bias.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="cam41256-kwd-0001">Aromatase</kwd>
<kwd id="cam41256-kwd-0002">arthralgia</kwd>
<kwd id="cam41256-kwd-0003">breast cancer</kwd>
<kwd id="cam41256-kwd-0004">estrogen</kwd>
<kwd id="cam41256-kwd-0005">joint pain</kwd>
<kwd id="cam41256-kwd-0006">
<styled-content style="fixed-case">SNP</styled-content>
</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>The Stefanie Spielman Breast Cancer Fund</funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="2"></table-count>
<page-count count="14"></page-count>
<word-count count="8463"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>cam41256</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.1 mode:remove_FC converted:19.01.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="cam41256-cit-1001" publication-type="self-citation">
<source/>Cancer Medicine
<year>2018</year>; 7(1):<fpage>240</fpage>–<lpage>253</lpage>
</mixed-citation>
</p>
</notes>
</front>
<body>
<sec id="cam41256-sec-0001">
<title>Introduction</title>
<p>Aromatase inhibitors (AIs) are critical to the management of women with hormone receptor‐positive breast cancer (BC). Their use has evolved to include premenopausal women with high‐risk BC in combination with ovarian suppression <xref ref-type="ref" rid="cam41256-bib-0001">1</xref>, <xref ref-type="ref" rid="cam41256-bib-0002">2</xref>. Whether administered as monotherapy, sequential therapy, or extended therapy, AIs favorably impact disease free survival <xref ref-type="ref" rid="cam41256-bib-0003">3</xref>. However, AIs are also associated with a number of toxicities, of which arthralgia (AIA) is among the most common and significant.</p>
<p>The broad range of reported incidence of AIA (5–47%) may be attributed to a lack of uniformity in diagnostic criteria to define the condition and casual reporting <xref ref-type="ref" rid="cam41256-bib-0004">4</xref>. In two studies specifically designed to identify AIA, the incidence of AIA was consistently reported near 50%, and did not vary across different third‐generation AIs <xref ref-type="ref" rid="cam41256-bib-0005">5</xref>, <xref ref-type="ref" rid="cam41256-bib-0006">6</xref>. Importantly, AIA frequently results in noncompliance with AI regimens or treatment discontinuation entirely, both of which adversely impact clinical outcomes <xref ref-type="ref" rid="cam41256-bib-0005">5</xref>, <xref ref-type="ref" rid="cam41256-bib-0007">7</xref>.</p>
<p>Several clinical risk factors for AIA have been reported, including time since last menstrual cycle <xref ref-type="ref" rid="cam41256-bib-0008">8</xref>, obesity, prior hormone replacement therapy <xref ref-type="ref" rid="cam41256-bib-0004">4</xref> or chemotherapy, particularly taxanes <xref ref-type="ref" rid="cam41256-bib-0006">6</xref>. The relationship between low estrogen levels and arthralgias has been well reported <xref ref-type="ref" rid="cam41256-bib-0009">9</xref>. Niravath argues that an inflammatory intermediary is a driver of low estrogen and AIA <xref ref-type="ref" rid="cam41256-bib-0004">4</xref>. However, a precise predictor of women most at risk for developing AIA is not yet established.</p>
<p>Several studies have assessed a potential genomic link to AIA risk <xref ref-type="ref" rid="cam41256-bib-0010">10</xref>, <xref ref-type="ref" rid="cam41256-bib-0011">11</xref>, <xref ref-type="ref" rid="cam41256-bib-0012">12</xref>. Aside from a common methodological approach relying on prospective candidate gene or single‐nucleotide polymorphism (SNP) selection for study, these investigations’ conclusions have varied. Despite such inconsistencies, we believe an alternative analytical approach may effectively identify germline mutations associated with an increased risk of moderate to severe forms of AIA. Furthermore, we believe gene attribution of these mutations might elucidate the pathophysiology underlying AIAs.</p>
<p>We devised a case–control study of women with early stage breast cancer with and without significant AIA. We favored methodology recognizing that risk amplification was more likely when groups of synergistically expressed SNPs occurred (rather than a single SNP) – a departure from the ‘magic bullet’ approach. Consequently, we adapted a novel analytical method, previously proven to be effective in a smaller number of patients, to identify an optimum cluster of SNPs that when expressed together, differentiate those patients at risk for AIA <xref ref-type="ref" rid="cam41256-bib-0013">13</xref>.</p>
</sec>
<sec id="cam41256-sec-0002">
<title>Patients and Methods</title>
<p>After Institutional Review Board permission was obtained, a systematic chart review of women enrolled in The Columbus Breast Cancer Tissue Bank was completed to identify patients receiving first‐line adjuvant treatment with third‐generation AIs (anastrazole, exemestane, letrozole) for at least 1 month to treat stage I‐III estrogen receptor‐positive BC between 2003 and 2012. Clinical efficacy of endocrine therapy was not captured in this investigation. Concurrent gonadotropin‐releasing (GnRH) agonist therapy, radiation therapy, prior tamoxifen use, and/or chemotherapy were allowed. Patients with metastatic disease or active autoimmune or inflammatory joint disease were excluded. Patients were divided into two groups: those with clinically significant AIA (defined as grade 2 or above by NCI‐CTCv.4 criteria) and/or requiring modification or termination of AI therapy, and those without any reported clinical signs or symptoms of AIA.</p>
<p>Germline DNA was extracted from mononuclear cells at the Human Cancer Genetics Sample Bank, The Ohio State University, according to previously published protocol <xref ref-type="ref" rid="cam41256-bib-0014">14</xref>. DNA was quantitated using PicoGreen and 200 ng of each DNA aliquoted into 96‐well plates. After sample elimination for poor quality DNA, SNP genotyping was performed along with appropriate controls. DNA amplification, fragmentation, and hybridization to Axiom UK Biobank genotyping arrays (Affymetrix, Santa Clara, CA) was completed using Axiom Reagent Kits; hybridization, ligation, washing, staining, and scanning of the arrays was completed on the GeneTitan MC instrument (Affymetrix). Initial plate QC was performed using Affymetrix Genotyping Console Software, and genotype calling done using Affymetrix Power Tools (v1.15.0) with the Axiom GT1 algorithm, which is a modified version of the BRLMM‐P algorithm that adapts generic prior cluster positions to the data using an EM algorithm.</p>
<sec id="cam41256-sec-0003">
<title>Analysis</title>
<p>To establish the parameters by which fold‐change thresholds were maximized to identify distinguishing SNPs, we considered SNPs in 3 groups: those uniquely associated with the AIA‐positive group, the AIA‐negative group, and those predominantly, but not uniquely associated with either group. We then assigned arbitrary numerical identifiers of 1, 2, or 3 to each group for parameterization and found that the maximum fold‐change defining a signal was log2 (3/1) = 1.59. Figure <xref ref-type="fig" rid="cam41256-fig-0001">1</xref> shows the flowchart of the methodology, which is composed of the following steps:</p>
<fig fig-type="Figure" id="cam41256-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Flowchart of the analytical steps used to identify those <styled-content style="fixed-case">SNP</styled-content>s most predictive of <styled-content style="fixed-case">AIA</styled-content> risk in the study population.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="CAM4-7-240-g001"></graphic>
</fig>
</sec>
<sec id="cam41256-sec-0004">
<title>Analysis of the discriminatory power of the SNPS</title>
<p>To identify the discriminatory power of those SNPs that were differentially noted between the AIA‐positive and ‐negative cohorts, we utilized a machine‐learning algorithm in which we combined fold change and Fisher's ratio. We defined the Fisher's ratio for a SNP <italic>j</italic> in a two‐class classification problem, <italic>c</italic>
<sub>1</sub>, <italic>c</italic>
<sub>2</sub> as:<disp-formula id="cam41256-disp-0001"><mml:math id="nlm-math-1"><mml:mrow><mml:msub><mml:mtext>FR</mml:mtext><mml:mi>j</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:msup></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="italic">μ</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>where <mml:math id="nlm-math-2"><mml:msubsup><mml:mi mathvariant="italic">μ</mml:mi><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math>
<mml:math id="nlm-math-3"><mml:msubsup><mml:mi mathvariant="italic">μ</mml:mi><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math> are measures of the center of the distribution (means) of prognostic variables <italic>j</italic> in classes 1 and 2 (AIA and no AIA), and <mml:math id="nlm-math-4"><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math>, <mml:math id="nlm-math-5"><mml:msubsup><mml:mi mathvariant="italic">σ</mml:mi><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math> are measures of the dispersion (variance) within these classes. This method is particularly effective for identifying prognostic/predictive variables that separate the classes further apart and are very homogeneous within classes (low intraclass variance).</p>
<p>We considered the 1% tail of the fold change (over and underexpressed SNPs), providing a final set of 436 high discriminatory SNPS with fold change in the interval [−0.31, 0.22] and Fisher's ratio greater than 1.5.</p>
</sec>
<sec id="cam41256-sec-0005">
<title>Finding the small‐scale SNPs signature</title>
<p>Once we identified those SNPs differentiating AIA‐positive and ‐negative patients, we ranked them in decreasing order based on their discriminatory power. Hypothesizing that optimization of predictive risk determination is most accurately the consequence of a collective effect from a cluster of SNPs, we then sought to identify the smallest aggregate of SNPs with the highest prognostic accuracy using an algorithm based on recursive elimination of lower discriminatory SNPs. Our analysis was based on the fact that high discriminatory variables served to span the main features of the classification (AIA), while the variables with lowest discriminatory ratios were of such granularity as to not markedly contribute to being informative as to differential risk. This method determined the minimum amount of high‐frequency details required to optimally discriminate between classes. The predictive accuracy estimation was based on Leave‐One‐Out‐Cross‐Validation (LOOCV) <xref ref-type="ref" rid="cam41256-bib-0010">10</xref>, <xref ref-type="ref" rid="cam41256-bib-0011">11</xref> given our goal to estimate how accurately the predictive model (classifier) would perform for future samples with an unknown AIA status.</p>
</sec>
<sec id="cam41256-sec-0006">
<title>Stability analysis of the small‐scale signature</title>
<p>By random 75–25 hold‐out experiments, we next evaluated the stability of the small‐scale signatures’ predictive accuracy (i.e., AIA contributions) found via LOOCV when the number of training samples was decreased. Due to absence of a totally independent clinical data set, the minimum‐scale signature was read in the training dataset for training (75% of the whole set) and applied for blind validation in the validation set (25%). The cumulative distribution function of the small‐scale predictive accuracies found in different hold‐outs was finally presented and accounted for the variability in its predictive accuracy with partial information. An additional statistical analysis was performed to provide the minimum, maximum, and median bounds that could be expected in an independent dataset. Figure <xref ref-type="fig" rid="cam41256-fig-0002">2</xref> shows the cumulative probability function of the predictive accuracy of the small‐scale signature obtained after 5000 random simulations.</p>
<fig fig-type="Figure" id="cam41256-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Stability analysis of the small‐scale signature of the 70 <styled-content style="fixed-case">SNP</styled-content>s which were identified as being most predictive of <styled-content style="fixed-case">AIA</styled-content> risk. The figure shows the cumulative distribution function of the predictive accuracy obtained after 5000 random 75/25 hold out simulations. It can be observed that the median accuracy (percentile 50) is around 75%, being the lower and upper‐quartiles 71% and 78%. The minimum and maximum accuracy achieved was 54% and 100%.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="CAM4-7-240-g002"></graphic>
</fig>
</sec>
<sec id="cam41256-sec-0007">
<title>Random sampling of high predictive SNPs equivalent networks</title>
<p>We next used a random sample to find other networks of highly discriminatory, prognostic SNPs. As the prior sampling probability of any individual SNP was considered to be proportional to its Fisher's ratio, we preferentially sampled the most discriminatory SNPs. To look at the impact of SNP synergism in enhancing risk prediction, we developed the most discriminatory networks and analyzed the posterior sampling frequencies of the main prognostic variables involved in each network. The analysis was completed by establishing the correlation network among the most discriminatory SNPs. The network was built using the maximum spanning tree algorithm (an acyclic graph that maximizes the value of the edges) and the Pearson correlation coefficient to identify those SNPS that showed the maximum positive and negative Pearson coefficient.</p>
</sec>
<sec id="cam41256-sec-0008">
<title>Gene attribution and functional analysis</title>
<p>We employed two different databases, NCBI Phenotype‐Genotype Integrator (NCBI PheGenI) <xref ref-type="ref" rid="cam41256-bib-0015">15</xref> and Ensemble release 88 <xref ref-type="ref" rid="cam41256-bib-0016">16</xref> using Genome assembly: GRCh38.p9, to gather the genes and their functional consequences associated with the top 70 most discriminatory SNPs (not shown).</p>
<p>To assess the functional validity of the SNP‐associated genes, we performed a comprehensive literature review of each gene associated with the most predictive SNPs, and summarized all relevant phenotypic attributions linking them to the following phenotypes: “arthralgia,” “synovial,” “arthritis,” “rheumatoid,” “joint,” “pain,” “sensitization,” and “nociception.” This was done via an ‘undirected’ review of all publications citing each gene, which was accessed via GeneAnalytics GeneCards’<xref ref-type="ref" rid="cam41256-bib-0017">17</xref> “Publications” section for each gene of interest <xref ref-type="ref" rid="cam41256-bib-0018">18</xref>.</p>
<p>We next determined the presence of any linkage disequilibrium (LD) among the 70 most discriminatory SNPs, as it is plausible that SNPs that individually have marginal influence on arthalgia risk‐associated genes may be inherited in linkage, and together as a group, synergistically increase arthralgia risk. Linkage disequilibrium was assessed by querying the 70 SNPs using Broad Institute's SNP Annotation and Proxy Search (SNAP) tool in the CEU (Utah residents with Northern and Western European ancestry) with <italic>R</italic>
<sup>2</sup> threshold of 0.8 and distance limit of 500 <xref ref-type="ref" rid="cam41256-bib-0019">19</xref>, <xref ref-type="ref" rid="cam41256-bib-0020">20</xref>.</p>
<p>As a final analysis of functional and phenotypic relevance of the gene set found to be influenced by the 70 SNPs, we applied an undirected assessment using GeneAnalytics software. We reasoned this would provide a relevance validation, but acknowledge the risk of overinterpretation of a small input. This program provides a semiquantitative output of gene cluster relationships relative to disease, pathway, and ontologic relationships. Relationships with “medium” and “high” matched scores for the diseases and pathways were reviewed.</p>
</sec>
</sec>
<sec id="cam41256-sec-0009">
<title>Results</title>
<p>Systematic chart review of 700 AI‐treated patients with stage I‐III BC identified asymptomatic patients (<italic>n</italic> = 39) and those with clinically significant AIA resulting in AI termination or therapy switch (<italic>n</italic> = 123). There were no significant demographic or disease differences between the AIA‐positive and ‐negative cohorts. Patients were similar in age (controls: 58.6 years, cases: 58.2 year), stage at diagnosis, and estrogen receptor status (Table <xref ref-type="table-wrap" rid="cam41256-tbl-0001">1</xref>). After sample elimination for poor‐quality DNA, SNP genotyping was performed for 123 AIA positive and 39 AIA negative patients.</p>
<table-wrap id="cam41256-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Comparative tumor characteristics of patients in the control (no AIA) and cases (clinically significant AIA) arms</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="char" colspan="1" rowspan="1" valign="top">Controls (<italic>N</italic> = 39) (%)</th>
<th align="char" colspan="1" rowspan="1" valign="top">Cases (<italic>N</italic> = 123) %</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Stage I</td>
<td align="char" char="(" colspan="1" rowspan="1">22 (56)</td>
<td align="char" char="(" colspan="1" rowspan="1">55 (45)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage II</td>
<td align="char" char="(" colspan="1" rowspan="1">14 (36)</td>
<td align="char" char="(" colspan="1" rowspan="1">54 (44)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage III</td>
<td align="char" char="(" colspan="1" rowspan="1">3 (8)</td>
<td align="char" char="(" colspan="1" rowspan="1">14 (11)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ER or PR positive/HER2 negative</td>
<td align="char" char="(" colspan="1" rowspan="1">33 (85)</td>
<td align="char" char="(" colspan="1" rowspan="1">104 (85)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ER or PR positive/HER2 positive</td>
<td align="char" char="(" colspan="1" rowspan="1">6 (15)</td>
<td align="char" char="(" colspan="1" rowspan="1">19 (15)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<sec id="cam41256-sec-0010">
<title>Discriminatory SNPs</title>
<p>Germline DNA was obtained and SNP genotyping performed to yield 695,277 SNPs. The analysis confirmed the importance of the main discriminatory SNPs (Table <xref ref-type="table-wrap" rid="cam41256-tbl-0002">2</xref>). Using the filtering sequence, after we determined and rank ordered the most discriminatory SNPs (<italic>n</italic> = 400), we identified the smallest number of SNPs that were most predictive of risk using the LOOCV algorithm described above. This method's overall predictive accuracy was calculated by iterating all of the filtered samples. We found that a signature consisting of 70 specific SNPs had the highest predictive accuracy of 75.93% (Table <xref ref-type="table-wrap" rid="cam41256-tbl-0002">2</xref>). Analysis of the SNP signature's predictive accuracy (Figure <xref ref-type="fig" rid="cam41256-fig-0002">2</xref>) demonstrated a median accuracy and true positive rate of 75.6% with an interquartile range of 7.3% and a true negative rate of 76.2%. The predictive accuracy's mean and standard deviation was 74.6% and 5.8%, respectively. The minimum and maximum accuracy of these random holds was 54% and 100%, which implies that the minimum size signature of SNPs is quite stable. While we cannot analyze how this predictive signature would vary when new patient data is acquired, we hypothesize the result will be similar to that described by the hold‐out experiments.</p>
<table-wrap id="cam41256-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>The seventy SNPs that defined AIA risk within the study population, and their possible functional relevance</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">SNP</th>
<th align="left" colspan="1" rowspan="1" valign="top">SNP Consequence</th>
<th align="left" colspan="1" rowspan="1" valign="top">Impacted Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">Gene's Relevant Phenotype Attributions</th>
<th align="left" colspan="1" rowspan="1" valign="top">Evidence/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">rs72765615</td>
<td align="left" colspan="1" rowspan="1">Intron Variant, 3′ UTR Variant</td>
<td align="left" colspan="1" rowspan="1">CHD2</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs17149310</td>
<td align="left" colspan="1" rowspan="1">Downstream Gene Variant</td>
<td align="left" colspan="1" rowspan="1">CFAP77</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs8028334</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">IL16</td>
<td align="left" colspan="1" rowspan="1">RA pathophysiology</td>
<td align="left" colspan="1" rowspan="1">Differentially elevated in synovial fluid from RA patients <xref ref-type="ref" rid="cam41256-bib-0025">25</xref>, <xref ref-type="ref" rid="cam41256-bib-0026">26</xref>, <xref ref-type="ref" rid="cam41256-bib-0044">44</xref>, <xref ref-type="ref" rid="cam41256-bib-0045">45</xref>, <xref ref-type="ref" rid="cam41256-bib-0046">46</xref>, <xref ref-type="ref" rid="cam41256-bib-0047">47</xref>, <xref ref-type="ref" rid="cam41256-bib-0048">48</xref> and mediates chemoattraction of CD4+ cells to synovial tissue <xref ref-type="ref" rid="cam41256-bib-0025">25</xref>, <xref ref-type="ref" rid="cam41256-bib-0026">26</xref>, <xref ref-type="ref" rid="cam41256-bib-0049">49</xref>, <xref ref-type="ref" rid="cam41256-bib-0050">50</xref>. However, IL16 correlation with clinical disease activity has been conflicting<xref ref-type="ref" rid="cam41256-bib-0045">45</xref>, <xref ref-type="ref" rid="cam41256-bib-0046">46</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs12004732</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">PLAA</td>
<td align="left" colspan="1" rowspan="1">RA pathophysiology</td>
<td align="left" colspan="1" rowspan="1">Detected in high levels in RA synovial fluid <xref ref-type="ref" rid="cam41256-bib-0022">22</xref> and may have inflammatory roles <xref ref-type="ref" rid="cam41256-bib-0051">51</xref>. Intrathecal injection in rabbit joints results in inflammatory arthritis<xref ref-type="ref" rid="cam41256-bib-0021">21</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs2883917</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">NR3C2</td>
<td align="left" colspan="1" rowspan="1">‐ Pain sensitization‐ Fibromyalgia</td>
<td align="left" colspan="1" rowspan="1">May be promote visceral hypersensitivity<xref ref-type="ref" rid="cam41256-bib-0036">36</xref>, and be implicated in pathophysiology of fibromyalgia<xref ref-type="ref" rid="cam41256-bib-0037">37</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs61363926</td>
<td align="left" colspan="1" rowspan="1">Noncoding Transcript Exon Variant</td>
<td align="left" colspan="1" rowspan="1">BANF1P2</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs56335940</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">LINC00882</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs3749817</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">FSTL4</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs879605</td>
<td align="left" colspan="1" rowspan="1">Intron variant, upstream variant 2KB</td>
<td align="left" colspan="1" rowspan="1">LTBR</td>
<td align="left" colspan="1" rowspan="1">RA pathophysiology</td>
<td align="left" colspan="1" rowspan="1">Induces RA synovial fibroblast proliferation and expression of inflammatory elements <xref ref-type="ref" rid="cam41256-bib-0028">28</xref>, <xref ref-type="ref" rid="cam41256-bib-0029">29</xref>. Associated with pain and disability in RA patients <xref ref-type="ref" rid="cam41256-bib-0027">27</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs879605</td>
<td align="left" colspan="1" rowspan="1">Intron variant, upstream variant 2KB</td>
<td align="left" colspan="1" rowspan="1">SCNN1A</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs986324</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">PTCHD1‐AS</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs7017819</td>
<td align="left" colspan="1" rowspan="1">Intron variant, Noncoding Transcript Exon Variant</td>
<td align="left" colspan="1" rowspan="1">RP1L1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs12799692</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">OPCML</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1">OPCML may bind opioids <xref ref-type="ref" rid="cam41256-bib-0052">52</xref>. It is also a tumor suppressor in and may be a marker of several types of tumors<xref ref-type="ref" rid="cam41256-bib-0053">53</xref>, <xref ref-type="ref" rid="cam41256-bib-0054">54</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs4394668</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">DHRS3</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs10996945</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">CTNNA3</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs10996945</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">LOC105378340</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs705226</td>
<td align="left" colspan="1" rowspan="1">Intron variant</td>
<td align="left" colspan="1" rowspan="1">LOC105374060</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs73042968</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">FBLN2</td>
<td align="left" colspan="1" rowspan="1">Breast cancer pathophysiology</td>
<td align="left" colspan="1" rowspan="1">Loss of FBLN2 expression is associated with breast cancer progression <xref ref-type="ref" rid="cam41256-bib-0055">55</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs1546734</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">LOC105377150</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs17270243</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">RORA‐AS1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs17270243</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">RORA*</td>
<td align="left" colspan="1" rowspan="1">‐ Breast cancer pathophysiology‐ Estrogen metabolism</td>
<td align="left" colspan="1" rowspan="1">‐ May suppress breast tumor invasion by inducing SEMA3F<xref ref-type="ref" rid="cam41256-bib-0056">56</xref>.‐ [Conflicting] Is a transcriptional regulator of aromatase <xref ref-type="ref" rid="cam41256-bib-0057">57</xref>. Activates aromatase expression in breast cancer cells, likely contributing to proliferation <xref ref-type="ref" rid="cam41256-bib-0058">58</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs5760686</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">SGSM1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs9907168</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">CDC42EP4</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs76098632</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">FBXL17</td>
<td align="left" colspan="1" rowspan="1">Breast cancer marker</td>
<td align="left" colspan="1" rowspan="1">May be a potential biomarker for breast cancer therapy<xref ref-type="ref" rid="cam41256-bib-0059">59</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs2243511</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">TMEM50B</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs2243511</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">IFNGR2</td>
<td align="left" colspan="1" rowspan="1">RA pathophysiology</td>
<td align="left" colspan="1" rowspan="1">‐Significant differences in blood mononuclear cell expression of IFNGR2 was seen in African American RA patients with erosion and those with no erosion <xref ref-type="ref" rid="cam41256-bib-0030">30</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs1012629</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">PTPRK</td>
<td align="left" colspan="1" rowspan="1">‐ RA pathophysiology‐ Breast cancer pathophysiology</td>
<td align="left" colspan="1" rowspan="1">‐Knocking down its encoded receptor impairs migration and invasiveness of RA fibroblast‐like synoviocytes (FLS), which otherwise progress to destroy cartilage and bone. This receptor mediates inflammatory signaling of TGF‐Beta in RA FLS <xref ref-type="ref" rid="cam41256-bib-0060">60</xref>.‐ Is a negative regulator of adhesion and invasion of breast cancer cells; its downregulation is associated with worse prognosis <xref ref-type="ref" rid="cam41256-bib-0061">61</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs322960</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">TRPV3</td>
<td align="left" colspan="1" rowspan="1">Pain sensitization</td>
<td align="left" colspan="1" rowspan="1">‐TRPV3 activation senses peripheral pain <xref ref-type="ref" rid="cam41256-bib-0024">24</xref>. It accumulates in peripheral nerves and dorsal root ganglion after injury <xref ref-type="ref" rid="cam41256-bib-0023">23</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs3743160</td>
<td align="left" colspan="1" rowspan="1">Intron Variant, 5′ UTR Variant</td>
<td align="left" colspan="1" rowspan="1">SLC28A1</td>
<td align="left" colspan="1" rowspan="1">Breast cancer pathophysiology</td>
<td align="left" colspan="1" rowspan="1">SLC28A1 expression may be implicated breast cancer cell responsiveness to chemotherapy <xref ref-type="ref" rid="cam41256-bib-0062">62</xref>, <xref ref-type="ref" rid="cam41256-bib-0063">63</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs797818</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">SEMA3A</td>
<td align="left" colspan="1" rowspan="1">‐ RA pathophysiology‐ OA pathophysiology</td>
<td align="left" colspan="1" rowspan="1">‐Reduced SEMA3A expression in human synovial tissues was associated with RA disease activity <xref ref-type="ref" rid="cam41256-bib-0031">31</xref>‐ SEMA3A expression is elevated in osteoarthritic cartilage, and inhibits VEGF's effects <xref ref-type="ref" rid="cam41256-bib-0064">64</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs11670284</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">NLRP13</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs2808787</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">COL27A1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">*Questionable relevance:‐ The temporal association and location of COL27A1 encoded collagen during calcification/transition of cartilage to bone suggests that the collagen is involved in the process. However, no specific roles have been elucidated <xref ref-type="ref" rid="cam41256-bib-0065">65</xref>.‐ A SNP in the region of COL27A1 (rs946053) occurred significantly more in a sample of patients with Achilles Tendinopathy, than in the control group <xref ref-type="ref" rid="cam41256-bib-0066">66</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs2215016</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">RGS6</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs3766160 and rs3820071</td>
<td align="left" colspan="1" rowspan="1">Missense Variant</td>
<td align="left" colspan="1" rowspan="1">CELA2B</td>
<td align="left" colspan="1" rowspan="1">Poorly studied.</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs10511813</td>
<td align="left" colspan="1" rowspan="1">Upstream variant 2KB</td>
<td align="left" colspan="1" rowspan="1">LOC105376002</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs12127403</td>
<td align="left" colspan="1" rowspan="1">Upstream Gene Variant</td>
<td align="left" colspan="1" rowspan="1">VHLL</td>
<td align="left" colspan="1" rowspan="1">Poorly studied.</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs10908495</td>
<td align="left" colspan="1" rowspan="1">Missense, Noncoding Transcript Variant</td>
<td align="left" colspan="1" rowspan="1">GLMP</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs11683506</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">SMARCAL1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs6081792</td>
<td align="left" colspan="1" rowspan="1">Intron Variant, Upstream Gene Variant</td>
<td align="left" colspan="1" rowspan="1">RIN2</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">*Questionable relevance:‐Deficiency of Encoded protein causes a congenital syndrome that includes severe joint hyperlaxity and scoliosis<xref ref-type="ref" rid="cam41256-bib-0067">67</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs1047312</td>
<td align="left" colspan="1" rowspan="1">3′ UTR Variant</td>
<td align="left" colspan="1" rowspan="1">SULT1C2</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs17011869</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">CNTNAP5</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs818399</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">LINC00922</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs11586047</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">LOC105371436</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs28964</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">SPACA3</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs10900269 and rs11239786</td>
<td align="left" colspan="1" rowspan="1">rs10900269 ‐ Intron Variant rs11239786 ‐ Noncoding Transcript Variant, Synonymous codon</td>
<td align="left" colspan="1" rowspan="1">BMS1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs11600377</td>
<td align="left" colspan="1" rowspan="1">Noncoding Transcript Exon Variant</td>
<td align="left" colspan="1" rowspan="1">MRGPRF‐AS1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs11600377</td>
<td align="left" colspan="1" rowspan="1">Upstream Gene Variant</td>
<td align="left" colspan="1" rowspan="1">MRGPRF</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">*Questionable relevance:‐ MRGPRF is a part of a family of proteins expressed in pain sensory neurons, and may be specifically activated by neuropeptides. However, MRGPRF, specifically, was not found in dorsal root ganglia in this study <xref ref-type="ref" rid="cam41256-bib-0068">68</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs62525208</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">C8orf37‐AS1</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs61782448</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">PLEKHM2</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs77413365</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">GRIA1</td>
<td align="left" colspan="1" rowspan="1">Inflammatory pain sensitization</td>
<td align="left" colspan="1" rowspan="1">‐ Trafficking of this Glutamate receptor in the central nervous system plays a role in inflammatory pain (TNF or IFN‐gamma mediated) and neuronal sensitization <xref ref-type="ref" rid="cam41256-bib-0034">34</xref>.‐ May also be implicated in inflammatory central sensitization of dorsal horn<xref ref-type="ref" rid="cam41256-bib-0033">33</xref>.‐Intrathecal injection of a painful inflammatory agent altered subcellular distribution of GRIA1, and decreased GRIA1 concentration in dorsal horn <xref ref-type="ref" rid="cam41256-bib-0032">32</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs1280408</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">CGNL1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">*Questionable relevance:‐The promoter of this gene may associate with the aromatase gene (due to a heterozygous inversion in chromosome 15q21.2‐3) to cause pathological aromatase and estrogen excess <xref ref-type="ref" rid="cam41256-bib-0069">69</xref>, <xref ref-type="ref" rid="cam41256-bib-0070">70</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs13013882</td>
<td align="left" colspan="1" rowspan="1">Splice Region Variant, Synonymous Codon</td>
<td align="left" colspan="1" rowspan="1">MROH2A</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs17599018</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">GPM6A</td>
<td align="left" colspan="1" rowspan="1">Pain sensitization</td>
<td align="left" colspan="1" rowspan="1">‐In cortical cultures of neurons, coexpression of GPM6A markedly increased the endocytosis of Mu‐type Opioid Receptors from plasma membrane to intracellular vesicles <xref ref-type="ref" rid="cam41256-bib-0035">35</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs2269767</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">UBFD1</td>
<td align="left" colspan="1" rowspan="1">Inflammatory antagonist</td>
<td align="left" colspan="1" rowspan="1">‐UBFD1‐encoded protein was identified as a polyubiquitin binder and may regulate NFkB activity through competitive antagonism of the NFkB pathway <xref ref-type="ref" rid="cam41256-bib-0038">38</xref>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs7024415</td>
<td align="left" colspan="1" rowspan="1">Downstream Gene Variant</td>
<td align="left" colspan="1" rowspan="1">ENSG00000253400</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs1546734</td>
<td align="left" colspan="1" rowspan="1">Intron Variant</td>
<td align="left" colspan="1" rowspan="1">ENSG00000242120</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">rs4785496</td>
<td align="left" colspan="1" rowspan="1">Upstream Gene Variant</td>
<td align="left" colspan="1" rowspan="1">ENSG00000260605</td>
<td align="left" colspan="1" rowspan="1">–</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="cam41256-note-0002">
<p>Seventy SNPs were identified which were associated with AIA risk. In addition to listing those SNPs, the consequence of each SNP is defined as is the gene most impacted by the mutation. Using literature mining as described in the Methods section, we determined the potential implication of genes relative to the development of AIA.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>The four most discriminating SNPs according to their sampling frequency as established by the random sampler were rs1462506, rs17149310, rs2883917, and rs10778060. The correlation network in Figure <xref ref-type="fig" rid="cam41256-fig-0003">3</xref> shows that the header SNP in the graph (rs7276615) is weakly, negatively correlated with rs11586047, rs6195687, rs10916270, and rs1462506. The main tree is developed under rs11586047, and the correlation coefficients are very low, suggesting that these SNPs are almost independent prognostic factors of the arthralgia phenotype. SNPS rs6195687, rs10916270, and rs1462506 are terminal nodes.</p>
<fig fig-type="Figure" id="cam41256-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Color visualization delineating the relationship of the 70 predictive <styled-content style="fixed-case">SNP</styled-content>s and their functional relevance. (A) Correlation tree of the most discriminatory <styled-content style="fixed-case">SNP</styled-content>s. This tree is built using the minimum spanning tree algorithm using the Pearson correlation coefficient. The algorithm looks for the maximum absolute values of the Pearson correlation coefficient (positive and negative correlations) within the set of most discriminatory <styled-content style="fixed-case">SNP</styled-content>s. This hierarchical figure describes the strength of relationships between <styled-content style="fixed-case">SNP</styled-content>s and how each <styled-content style="fixed-case">SNP</styled-content> relates to the others in the cluster.(B) Associated phenotypes include similar phenotypes (<styled-content style="fixed-case">RA</styled-content>, pain, inflammation and those associated with the tumor diagnosis).</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="CAM4-7-240-g003"></graphic>
</fig>
</sec>
<sec id="cam41256-sec-0011">
<title>Functional validity and gene attribution</title>
<p>To assess the potential functional validity of the 70 most predictive SNPs, we assessed gene attribution for each SNP and found that 57 genes were associated with the 70 SNPs of interest, with four genes linked to consequences from two or more SNPs (rs12004732 and rs7863476, variants of <italic>PLAA</italic>; rs322960 and rs60292929, variants of <italic>TRPV3</italic>; rs3766160 and rs3820071, variants of <italic>CELA2B</italic>, and rs10900269 and rs11239786, variants of <italic>BMS1</italic>). Assuming that an increase in the ratio of SNP to gene could suggest a more influential impact of arthalgia risk prediction by that gene, we evaluated the relationship between the aforementioned genes and arthalgia‐related phenotypes.</p>
<p>Following the search strategy defined above, we noted that both <italic>PLAA</italic> and <italic>TRPV3</italic> had relevant associations with arthalgia phenotypes. <italic>PLAA</italic> is implicated in inflammatory pathways of synovial cells from Rheumatoid Arthritis (RA) patients <xref ref-type="ref" rid="cam41256-bib-0021">21</xref>, <xref ref-type="ref" rid="cam41256-bib-0022">22</xref>, and caused inflammatory arthritis when injected into rabbit knee joints <xref ref-type="ref" rid="cam41256-bib-0021">21</xref>. <italic>TRPV3</italic> accumulates in peripheral nerves and dorsal root ganglion <xref ref-type="ref" rid="cam41256-bib-0023">23</xref>, and its activation is implicated in sensing peripheral pain <xref ref-type="ref" rid="cam41256-bib-0024">24</xref>. Associations of <italic>CELA2B</italic> are poorly understood. Lastly, there is no primary data to suggest a direct relationship between <italic>BMS1</italic>, arthralgias or BC, although <italic>BMS1</italic> is also poorly studied. The potential synergistic impact of these genes on AIA risk requires additional study.</p>
<p>In addition to the four genes above, 19 of the other 57 genes associated with the top 70 SNPs were linked to phenotypes involving BC, estrogen metabolism, and significantly, arthralgia. Some of these arthralgia associations include <italic>IL16</italic> (was significantly elevated in synovial fluid of RA patients and mediated chemoattraction of CD4 +  cells into synovial tissues <xref ref-type="ref" rid="cam41256-bib-0025">25</xref>, <xref ref-type="ref" rid="cam41256-bib-0026">26</xref>), <italic>LTBR</italic> (its expression in RA patients’ synovium positively associated with pain and disability <xref ref-type="ref" rid="cam41256-bib-0027">27</xref>, and may be implicated in RA synovial fibroblast proliferation and expression of inflammatory elements <xref ref-type="ref" rid="cam41256-bib-0028">28</xref>, <xref ref-type="ref" rid="cam41256-bib-0029">29</xref>), <italic>IFNGR2</italic> (joint erosion, joint space narrowing, and disease progression was significantly associated with differential expression of <italic>IFNGR2</italic> in blood mononuclear cells of African American RA patients with radiographic erosion compared to patients with no erosion <xref ref-type="ref" rid="cam41256-bib-0030">30</xref>), <italic>SEMA3A</italic> (expressed in synovial tissues and associated with RA <xref ref-type="ref" rid="cam41256-bib-0031">31</xref>), <italic>GRIA1</italic> (implicated in inflammatory pain and central sensitization of dorsal horns <xref ref-type="ref" rid="cam41256-bib-0032">32</xref>, <xref ref-type="ref" rid="cam41256-bib-0033">33</xref>, <xref ref-type="ref" rid="cam41256-bib-0034">34</xref>), <italic>GPM6A</italic> (associated with endocytosis of Mu‐type opioid receptors in neuronal cortical cell cultures <xref ref-type="ref" rid="cam41256-bib-0035">35</xref>), <italic>NR3C2</italic> (may promote visceral hypersensitivity <xref ref-type="ref" rid="cam41256-bib-0036">36</xref> and may be implicated in pathophysiology of fibromyalgia <xref ref-type="ref" rid="cam41256-bib-0037">37</xref>), and lastly, <italic>UBFD1</italic> (implicated as a regulator of NFkB pathway <xref ref-type="ref" rid="cam41256-bib-0038">38</xref>) (Table <xref ref-type="table-wrap" rid="cam41256-tbl-0002">2</xref>).</p>
</sec>
<sec id="cam41256-sec-0012">
<title>Linkage disequilibrium</title>
<p>The LD analysis found 3 sets of SNPs among the top 70 SNP to be in LD. The first LD pair included rs3766160 and rs3820071, missense mutations of <italic>CELA2B</italic>, a poorly characterized gene. The second pair includes LD between rs12127403 (Upstream Gene Variant of <italic>VHLL</italic>, which competetively prevents degradation of HIF‐alpha <xref ref-type="ref" rid="cam41256-bib-0039">39</xref>) and rs10908495 (a variant of <italic>GLMP</italic>, another poorly characterized gene). The last pair consisted of rs3011665 and rs981360, which are not known to consequence any specific genes.</p>
</sec>
</sec>
<sec id="cam41256-sec-0013">
<title>Discussion</title>
<p>AIA is a prevalent and disrupting toxicity of AIs, impacting quality of life, adherence and clinical outcomes <xref ref-type="ref" rid="cam41256-bib-0040">40</xref>. As with other regimen‐related toxicities, the risk for AIA is not consistent among patients receiving identical treatments for the same disease. The ability to prospectively differentiate patients at risk for AIA would be desirable at a number of levels, but most importantly in providing actionable data that could inform clinician and patient decision‐making, as well as leading to the design of intervention trials focused on high‐risk individuals. Additionally, the identification of a predictive biomarker strongly associated with a clinically meaningful manifestation of AIA could provide a surrogate for its more accurate reporting.</p>
<p>To identify the SNPs of interest, we used a machine‐learning algorithm for which the SNPs of interest were not pre‐determined. Rather, employing a previously validated technique, we used a filtering step to create a hierarchal list of SNPs most associated with the AIA phenotype while simultaneously eliminating SNPs that were simply genomic “noise” <xref ref-type="ref" rid="cam41256-bib-0013">13</xref>. We were able to reduce nearly 400,000 SNPs by three logs to approximately 450 SNPs. We then asked which SNPs were most predictive as a ‘team’ and, using a method in which we sequentially tested every combination of SNPs, identified 70 SNPs that collectively predicted AIA with fair accuracy (75.93%).</p>
<p>Attempts to determine AIA risk‐based strictly on demographic features have been only marginally successful. We found no differences in the study cohorts’ clinical or demographic characteristics. The application of genomic markers, particularly SNPs, as a means to assess toxicity risk associated with cancer treatment regimens has been studied broadly, but with wide ranging and often inconsistent results. In general, two approaches have been used: candidate gene or SNP studies and GWAS. Investigations of genomic risk factors for AIA have exclusively depended on candidate gene/SNP identification.</p>
<p>Since <italic>CYP19A1</italic> codes for the aromatase enzyme in postmenopausal women, it has been an obvious candidate gene for AIA risk prediction <xref ref-type="ref" rid="cam41256-bib-0041">41</xref>. While three studies have studied polymorphisms associated with <italic>CYP19A1</italic> relative to AIA and found an association, there is variability in the SNPs reported <xref ref-type="ref" rid="cam41256-bib-0012">12</xref>, <xref ref-type="ref" rid="cam41256-bib-0041">41</xref>, <xref ref-type="ref" rid="cam41256-bib-0042">42</xref>, <xref ref-type="ref" rid="cam41256-bib-0043">43</xref>. Other polymorphisms associated with estrogen and vitamin D metabolism have also been targeted. While analyzing such SNPs for risk prediction, Garcia‐Giralt and her colleagues introduced multiplicative terms into their analysis, thus providing a conceptual basis for synergism in contributing to AIA risk <xref ref-type="ref" rid="cam41256-bib-0012">12</xref>. In a related investigation, Lintermans et al. reported that a SNP associated with the osteoprotegrin gene was associated with adverse symptoms (hot flashes and pain) in patients treated with AIs <xref ref-type="ref" rid="cam41256-bib-0010">10</xref>.</p>
<p>A drawback of candidate gene studies is that they limit discovery of phenotype‐associated genes or SNPs that may not be obvious to investigators deciding on targets. Analogous to trying to describe a landscape in the dark by shining a flashlight with a narrow beam, candidate gene studies may miss important features. Consequently, we took an analytical approach that differed from conventional paradigms in three important ways: (1) we did not mandate a threshold gene expression (SNP) level change for inclusion; (2) we evaluated simultaneous expression of SNP profiles (clusters); (3) the predictive clusters that evolved were driven by their collective and hierarchical relationships with the study groups rather than dependent on preconceptions of an expected result. Importantly, we were able to confirm the relevance of the discovered clusters by confirming their fit into known ontological pathways.</p>
<p>To determine the functional validity of the SNPs in the cluster, we attributed SNPs to their related genes (<italic>n</italic> = 57) and evaluated relevance to several phenotypes that we thought may be expressed in the study cohort. Many individual SNPs were functionally specific for arthralgia‐like disease phenotypes. Others were associated with estrogen metabolism – a finding that supports the hypotheses suggested by the <italic>CYP21A</italic> candidate studies. None of the SNPs in this cluster were attributable to <italic>CYP21A</italic> genes, which may be a component of faults in SNP and gene designation. Genes associated with pain sensitization were notable, a finding theoretically similar to the interests of Lintemans et al <xref ref-type="ref" rid="cam41256-bib-0010">10</xref>. Interestingly, genes associated with RA pathophysiology were relatively high in the cluster, suggesting a common biological pathway with AIA and in congruence with other findings implicating an inflammatory mechanism. One SNP in the cluster was closely aligned with inflammation.</p>
<p>Although we included internal cross‐validation in this study, the investigation was limited by small sample size and our inability to have an independent validation cohort. We believe that increasing the training sample will result in a more robust predictive accuracy. An independent validation cohort will be critical to understanding the true clinical meaningfulness and translatability of our findings. A prospective study is currently underway to address these shortcomings.</p>
<p>Nonetheless, we believe that this trial demonstrates the potential utility of an undirected, machine‐learning approach in the development of a predictive test for AIA risk. Such a personalized model in which at‐risk patients are identified prior to therapy start may help to minimize toxicity by prompting the early institution of preventative, therapeutic, or alternative interventions, and thus improve treatment adherence and disease outcomes.</p>
</sec>
<sec id="cam41256-sec-0014">
<title>Conflict of Interest</title>
<p>Disclosures outside the submitted work are noted. Stephen Sonis, Ohio State University (grants), Primary Endpoint Solutions LLC (equity), Biomodels LLC (employee), Inform Genomics (equity); Juan Luis Fernández‐Martínez Primary Endpoint Solutions LLC (consultant); Ana Cernea Primary Endpoint Solutions LLC (consultant); Enrique J. de Andrés‐Galiana Primary Endpoint Solutions LLC (consultant).</p>
</sec>
</body>
<back>
<ref-list content-type="cited-references" id="cam41256-bibl-0001">
<title>References</title>
<ref id="cam41256-bib-0001">
<label>1</label>
<mixed-citation id="cam41256-cit-0001" publication-type="journal">
<string-name>
<surname>Pagani</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Regan</surname>
</string-name>, and <string-name>
<given-names>P. A.</given-names>
<surname>Francis</surname>
</string-name>. <year>2014</year>
<article-title>Investigators TaS, group IBCS. Exemestane with ovarian suppression in premenopausal breast cancer</article-title>. <source/>N. Engl. J. Med.
<volume>371</volume>:<fpage>1358</fpage>–<lpage>1359</lpage>.</mixed-citation>
</ref>
<ref id="cam41256-bib-0002">
<label>2</label>
<mixed-citation id="cam41256-cit-0002" publication-type="journal">
<string-name>
<surname>Francis</surname>, <given-names>P. A.</given-names>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Regan</surname>
</string-name>, and <string-name>
<given-names>G. F.</given-names>
<surname>Fleming</surname>
</string-name>. <year>2015</year>
<article-title>Adjuvant ovarian suppression in premenopausal breast cancer</article-title>. <source/>N. Engl. J. Med.
<volume>372</volume>:<fpage>1673</fpage>.</mixed-citation>
</ref>
<ref id="cam41256-bib-0003">
<label>3</label>
<mixed-citation id="cam41256-cit-0003" publication-type="journal">
<string-name>
<surname>Aydiner</surname>, <given-names>A.</given-names>
</string-name>. <year>2013</year>
<article-title>Meta‐analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women</article-title>. <source/>Breast (Edinburgh, Scotland) <volume>22</volume>:<fpage>121</fpage>–<lpage>129</lpage>.<pub-id pub-id-type="pmid">23462682</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0004">
<label>4</label>
<mixed-citation id="cam41256-cit-0004" publication-type="journal">
<string-name>
<surname>Niravath</surname>, <given-names>P.</given-names>
</string-name>
<year>2013</year>
<article-title>Aromatase inhibitor‐induced arthralgia: a review</article-title>. <source/>Ann. Oncol.
<volume>24</volume>:<fpage>1443</fpage>–<lpage>1449</lpage>.<pub-id pub-id-type="pmid">23471104</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0005">
<label>5</label>
<mixed-citation id="cam41256-cit-0005" publication-type="journal">
<string-name>
<surname>Henry</surname>, <given-names>N. L.</given-names>
</string-name>, <string-name>
<given-names>J. T.</given-names>
<surname>Giles</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Henry</surname>
</string-name>, <string-name>
<given-names>Jon. T.</given-names>
<surname>Giles</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mohan</surname>
</string-name>, et al. <year>2008</year>
<article-title>Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors</article-title>. <source/>Breast Cancer Res. Treat.
<volume>111</volume>:<fpage>365</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">17922185</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0006">
<label>6</label>
<mixed-citation id="cam41256-cit-0006" publication-type="journal">
<string-name>
<surname>Crew</surname>, <given-names>Katherine. D.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Greenlee</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Capodice</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Raptis</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Brafman</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Fuentes</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sierra</surname>
</string-name>, <string-name>
<given-names>Dawn. L.</given-names>
<surname>Hershman</surname>
</string-name>, et al. <year>2007</year>
<article-title>Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early‐stage breast cancer</article-title>. <source/>J. Clin. Oncol.
<volume>25</volume>:<fpage>3877</fpage>–<lpage>3883</lpage>.<pub-id pub-id-type="pmid">17761973</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0007">
<label>7</label>
<mixed-citation id="cam41256-cit-0007" publication-type="journal">
<string-name>
<surname>Partridge</surname>, <given-names>A. H.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>LaFountain</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Mayer</surname>
</string-name>, <string-name>
<given-names>B. S.</given-names>
<surname>Taylor</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Winer</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Asnis‐Alibozek</surname>
</string-name>. <year>2008</year>
<article-title>Adherence to initial adjuvant anastrozole therapy among women with early‐stage breast cancer</article-title>. <source/>J. Clin. Oncol.
<volume>26</volume>:<fpage>556</fpage>–<lpage>562</lpage>.<pub-id pub-id-type="pmid">18180462</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0008">
<label>8</label>
<mixed-citation id="cam41256-cit-0008" publication-type="journal">
<string-name>
<surname>Mao</surname>, <given-names>Jun. J.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Stricker</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Bruner</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>Marjorie. A.</given-names>
<surname>Bowman</surname>
</string-name>, <string-name>
<given-names>John. T.</given-names>
<surname>Farrar</surname>
</string-name>, <string-name>
<given-names>Brandon. T.</given-names>
<surname>Greene</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>DeMichele</surname>
</string-name>, et al. <year>2009</year>
<article-title>Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors</article-title>. <source/>Cancer
<volume>115</volume>:<fpage>3631</fpage>–<lpage>3639</lpage>.<pub-id pub-id-type="pmid">19517460</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0009">
<label>9</label>
<mixed-citation id="cam41256-cit-0009" publication-type="journal">
<string-name>
<surname>Cecil</surname>, <given-names>R. L.</given-names>
</string-name>, and <string-name>
<given-names>B. H.</given-names>
<surname>Archer</surname>
</string-name>. <year>1925</year>
<article-title>Arthritis of the menopause: a study of fifty cases</article-title>. <source/>J. Am. Med. Assoc.
<volume>84</volume>:<fpage>75</fpage>–<lpage>79</lpage>.</mixed-citation>
</ref>
<ref id="cam41256-bib-0010">
<label>10</label>
<mixed-citation id="cam41256-cit-0010" publication-type="journal">
<string-name>
<surname>Lintermans</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Van Asten</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Jongen</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Van Brussel</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Laenen</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Verhaeghe</surname>
</string-name>, et al. <year>2016</year>
<article-title>Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor‐related musculoskeletal toxicity in breast cancer patients</article-title>. <source/>Eur. J. Cancer (Oxford, England: 1990)<volume>56</volume>:<fpage>31</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">26798969</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0011">
<label>11</label>
<mixed-citation id="cam41256-cit-0011" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Kangping</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Song</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Xuan</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhang</surname>
</string-name>, et al. <year>2015</year>
<article-title>RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor‐Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients</article-title>. <source/>PLoS ONE
<volume>10</volume>:<fpage>e0133964</fpage>.<pub-id pub-id-type="pmid">26218592</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0012">
<label>12</label>
<mixed-citation id="cam41256-cit-0012" publication-type="journal">
<string-name>
<surname>Garcia‐Giralt</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Rodríguez‐Sanz</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Prieto‐Alhambra</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Servitja</surname>
</string-name>, <string-name>
<given-names>E. T.‐d.</given-names>
<surname>Pliego</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Balcells</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Albanell</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Grinberg</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Diez‐Perez</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Tusquets</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Nogués</surname>
</string-name>, et al. <year>2013</year>
<article-title>Genetic determinants of aromatase inhibitor‐related arthralgia: the B‐ABLE cohort study</article-title>. <source/>Breast Cancer Res. Treat.
<volume>140</volume>:<fpage>385</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">23868189</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0013">
<label>13</label>
<mixed-citation id="cam41256-cit-0013" publication-type="journal">
<string-name>
<surname>Saligan</surname>, <given-names>L. N.</given-names>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Fernández‐Martínez</surname>
</string-name>, <string-name>
<given-names>E. J.</given-names>
<surname>deAndrés‐Galiana</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Sonis</surname>
</string-name>. <year>2014</year>
<article-title>Supervised classification by filter methods and recursive feature elimination predicts risk of radiotherapy‐related fatigue in patients with prostate cancer</article-title>. <source/>Cancer Inform.
<volume>13</volume>:<fpage>141</fpage>–<lpage>152</lpage>.<pub-id pub-id-type="pmid">25506196</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0014">
<label>14</label>
<mixed-citation id="cam41256-cit-0014" publication-type="journal">
<string-name>
<surname>Miller</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<given-names>D. D.</given-names>
<surname>Dykes</surname>
</string-name>, and <string-name>
<given-names>H. F.</given-names>
<surname>Polesky</surname>
</string-name>. <year>1988</year>
<article-title>A simple salting out procedure for extracting DNA from human nucleated cells</article-title>. <source/>Nucleic Acids Res.
<volume>16</volume>:<fpage>1215</fpage>.<pub-id pub-id-type="pmid">3344216</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0015">
<label>15</label>
<mixed-citation id="cam41256-cit-0015" publication-type="journal">
<string-name>
<surname>Ramos</surname>, <given-names>Erin. M.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Hoffman</surname>
</string-name>, <string-name>
<given-names>Heather. A.</given-names>
<surname>Junkins</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Maglott</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Phan</surname>
</string-name>, <string-name>
<given-names>Stephen. T.</given-names>
<surname>Sherry</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Feolo</surname>
</string-name>, <string-name>
<given-names>Lucia. A.</given-names>
<surname>Hindorff</surname>
</string-name>, et al. <year>2014</year>
<article-title>Phenotype‐Genotype Integrator (PheGenI): synthesizing genome‐wide association study (GWAS) data with existing genomic resources</article-title>. <source/>Eur. J. Hum. Genet.
<volume>22</volume>:<fpage>144</fpage>–<lpage>147</lpage>.<pub-id pub-id-type="pmid">23695286</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0016">
<label>16</label>
<mixed-citation id="cam41256-cit-0016" publication-type="journal">
<string-name>
<surname>Yates</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Wasiu Akanni</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Amode</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Barrell</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Billis</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Carvalho‐Silva</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Cummins</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Clapham</surname>
</string-name>, et al. <year>2016</year>
<article-title>Ensembl 2016</article-title>. <source/>Nucleic Acids Res.
<volume>44</volume>(<issue>D1</issue>):<fpage>D710</fpage>–<lpage>716</lpage>.<pub-id pub-id-type="pmid">26687719</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0017">
<label>17</label>
<mixed-citation id="cam41256-cit-0017" publication-type="journal">
<string-name>
<surname>Fuchs</surname>, <given-names>S. B.‐A.</given-names>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Lieder</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Stelzer</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mazor</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Buzhor</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kaplan</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Bogoch</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Plaschkes</surname>
</string-name>, et al. <year>2016</year>
<article-title>GeneAnalytics: an integrative gene set analysis tool for next generation sequencing, rnaseq and microarray data</article-title>. <source/>OMICS
<volume>20</volume>:<fpage>139</fpage>–<lpage>151</lpage>.<pub-id pub-id-type="pmid">26983021</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0018">
<label>18</label>
<mixed-citation id="cam41256-cit-0018" publication-type="journal">
<string-name>
<surname>Stelzer</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Rosen</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Plaschkes</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Zimmerman</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Twik</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Fishilevich</surname>
</string-name>, <string-name>
<given-names>T. I.</given-names>
<surname>Stein</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Nudel</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Lieder</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Mazor</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kaplan</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Dahary</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Warshawsky</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Guan‐Golan</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kohn</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Rappaport</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Safran</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Lancet</surname>
</string-name>, et al. <year>2016</year>
<article-title>The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses</article-title>. <source/>Curr. Protoc. Bioinformatics.
<volume>54</volume>:<fpage>1.30.31‐31.30.33</fpage>.<pub-id pub-id-type="pmid">27322403</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0019">
<label>19</label>
<mixed-citation id="cam41256-cit-0019" publication-type="journal">
<string-name>
<surname>Johnson</surname>, <given-names>A. D.</given-names>
</string-name>, <string-name>
<given-names>R. E.</given-names>
<surname>Handsaker</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Pulit</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Nizzari</surname>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>O'Donnell</surname>
</string-name>, and <string-name>
<given-names>P. I.</given-names>
<surname>de Bakker</surname>
</string-name>. <year>2008</year>
<article-title>SNAP: a web‐based tool for identification and annotation of proxy SNPs using HapMap</article-title>. <source/>Bioinformatics
<volume>24</volume>:<fpage>2938</fpage>–<lpage>2939</lpage>.<pub-id pub-id-type="pmid">18974171</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0020">
<label>20</label>
<mixed-citation id="cam41256-cit-0020" publication-type="journal">
<string-name>
<surname>Frazer</surname>, <given-names>Kelly. A.</given-names>
</string-name>, <string-name>
<given-names>Dennis. G.</given-names>
<surname>Ballinger</surname>
</string-name>, <string-name>
<given-names>David. R.</given-names>
<surname>Cox</surname>
</string-name>, <string-name>
<given-names>David. A.</given-names>
<surname>Hinds</surname>
</string-name>, <string-name>
<given-names>Laura. L.</given-names>
<surname>Stuve</surname>
</string-name>, <string-name>
<given-names>Richard. A.</given-names>
<surname>Gibbs</surname>
</string-name>, <string-name>
<given-names>John. W.</given-names>
<surname>Belmont</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Boudreau</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Hardenbol</surname>
</string-name>, <string-name>
<given-names>Suzanne. M.</given-names>
<surname>Leal</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Pasternak</surname>
</string-name>, <string-name>
<given-names>David. A.</given-names>
<surname>Wheeler</surname>
</string-name>, <string-name>
<given-names>Thomas. D.</given-names>
<surname>Willis</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Fuli</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Gao</surname>
</string-name>, et al. <year>2007</year>
<article-title>A second generation human haplotype map of over 3.1 million SNPs</article-title>. <source/>Nature
<volume>449</volume>:<fpage>851</fpage>–<lpage>861</lpage>.<pub-id pub-id-type="pmid">17943122</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0021">
<label>21</label>
<mixed-citation id="cam41256-cit-0021" publication-type="journal">
<string-name>
<surname>Bomalaski</surname>, <given-names>J. S.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fallon</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Turner</surname>
</string-name>, <string-name>
<given-names>S. T.</given-names>
<surname>Crooke</surname>
</string-name>, <string-name>
<given-names>P. C.</given-names>
<surname>Meunier</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Clark</surname>
</string-name>. <year>1990</year>
<article-title>Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo</article-title>. <source/>J. Lab. Clin. Med.
<volume>116</volume>:<fpage>814</fpage>–<lpage>825</lpage>.<pub-id pub-id-type="pmid">2246557</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0022">
<label>22</label>
<mixed-citation id="cam41256-cit-0022" publication-type="journal">
<string-name>
<surname>Goddard</surname>, <given-names>D. H.</given-names>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Grossman</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Newton</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Clark</surname>
</string-name>, and <string-name>
<given-names>J. S.</given-names>
<surname>Bomalaski</surname>
</string-name>. <year>1992</year>
<article-title>Regulation of synovial cell growth: basic fibroblast growth factor synergizes with interleukin 1 beta stimulating phospholipase A2 enzyme activity, phospholipase A2 activating protein production and release of prostaglandin E2 by rheumatoid arthritis synovial cells in culture</article-title>. <source/>Cytokine
<volume>4</volume>:<fpage>377</fpage>–<lpage>384</lpage>.<pub-id pub-id-type="pmid">1420999</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0023">
<label>23</label>
<mixed-citation id="cam41256-cit-0023" publication-type="journal">
<string-name>
<surname>Facer</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>Maria. A.</given-names>
<surname>Casula</surname>
</string-name>, <string-name>
<given-names>Graham. D.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>Christopher. D.</given-names>
<surname>Benham</surname>
</string-name>, <string-name>
<given-names>Iain. P.</given-names>
<surname>Chessell</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bountra</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sinisi</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Birch</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Anand</surname>
</string-name>, et al. <year>2007</year>
<article-title>Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy</article-title>. <source/>BMC Neurol.
<volume>7</volume>:<fpage>11</fpage>.<pub-id pub-id-type="pmid">17521436</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0024">
<label>24</label>
<mixed-citation id="cam41256-cit-0024" publication-type="journal">
<string-name>
<surname>Bang</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Yoo</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Cho</surname>
</string-name>, and <string-name>
<given-names>S. W.</given-names>
<surname>Hwang</surname>
</string-name>. <year>2010</year>
<article-title>Farnesyl pyrophosphate is a novel pain‐producing molecule via specific activation of TRPV3</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>:<fpage>19362</fpage>–<lpage>19371</lpage>.<pub-id pub-id-type="pmid">20395302</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0025">
<label>25</label>
<mixed-citation id="cam41256-cit-0025" publication-type="journal">
<string-name>
<surname>Franz</surname>, <given-names>Juliane. K.</given-names>
</string-name>, <string-name>
<given-names>Stefan. A.</given-names>
<surname>Kolb</surname>
</string-name>, <string-name>
<given-names>Klaus. M.</given-names>
<surname>Hummel</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Lahrtz</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Neidhart</surname>
</string-name>, <string-name>
<given-names>Wilhelm. K.</given-names>
<surname>Aicher</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Pap</surname>
</string-name>, <string-name>
<given-names>Renate. E.</given-names>
<surname>Gay</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fontana</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Gay</surname>
</string-name>, et al. <year>1998</year>
<article-title>Interleukin‐16, produced by synovial fibroblasts, mediates chemoattraction for CD4 + T lymphocytes in rheumatoid arthritis</article-title>. <source/>Eur. J. Immunol.
<volume>28</volume>:<fpage>2661</fpage>–<lpage>2671</lpage>.<pub-id pub-id-type="pmid">9754554</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0026">
<label>26</label>
<mixed-citation id="cam41256-cit-0026" publication-type="journal">
<string-name>
<surname>Warstat</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hoberg</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Rudert</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Tsui</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Pap</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Angres</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Essl</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>W. W.</given-names>
<surname>Cruikshank</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Klein</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Gay</surname>
</string-name>, <string-name>
<given-names>W. K.</given-names>
<surname>Aicher</surname>
</string-name>, et al. <year>2010</year>
<article-title>Transforming growth factor beta1 and laminin‐111 cooperate in the induction of interleukin‐16 expression in synovial fibroblasts from patients with rheumatoid arthritis</article-title>. <source/>Ann. Rheum. Dis.
<volume>69</volume>:<fpage>270</fpage>–<lpage>275</lpage>.<pub-id pub-id-type="pmid">19279017</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0027">
<label>27</label>
<mixed-citation id="cam41256-cit-0027" publication-type="journal">
<string-name>
<surname>O'Rourke</surname>, <given-names>Killian. P.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>O'Donoghue</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Adams</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Mulcahy</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Molloy</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Silke</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Molloy</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Shanahan</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>O'Gara</surname>
</string-name>, et al. <year>2008</year>
<article-title>High levels of Lymphotoxin‐Beta (LT‐Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations</article-title>. <source/>Rheumatol. Int.
<volume>28</volume>:<fpage>979</fpage>–<lpage>986</lpage>.<pub-id pub-id-type="pmid">18379788</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0028">
<label>28</label>
<mixed-citation id="cam41256-cit-0028" publication-type="journal">
<string-name>
<surname>Ishida</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Yamane</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ochi</surname>
</string-name>, et al. <year>2008</year>
<article-title>LIGHT induces cell proliferation and inflammatory responses of rheumatoid arthritis synovial fibroblasts via lymphotoxin beta receptor</article-title>. <source/>J. Rheumatol.
<volume>35</volume>:<fpage>960</fpage>–<lpage>968</lpage>.<pub-id pub-id-type="pmid">18412315</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0029">
<label>29</label>
<mixed-citation id="cam41256-cit-0029" publication-type="journal">
<string-name>
<surname>Edwards</surname>, <given-names>J. R.</given-names>
</string-name>, <string-name>
<given-names>S. G.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Locklin</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Shipman</surname>
</string-name>, <string-name>
<given-names>I. E.</given-names>
<surname>Adamopoulos</surname>
</string-name>, <string-name>
<given-names>N. A.</given-names>
<surname>Athanasou</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sabokbar</surname>
</string-name>, et al. <year>2006</year>
<article-title>LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis</article-title>. <source/>Arthritis Rheum.
<volume>54</volume>:<fpage>1451</fpage>–<lpage>1462</lpage>.<pub-id pub-id-type="pmid">16649193</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0030">
<label>30</label>
<mixed-citation id="cam41256-cit-0030" publication-type="journal">
<string-name>
<surname>Tang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<given-names>M. I.</given-names>
<surname>Danila</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Cui</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Parks</surname>
</string-name>, <string-name>
<given-names>B. J.</given-names>
<surname>Baker</surname>
</string-name>, <string-name>
<given-names>R. J.</given-names>
<surname>Reynolds</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Raman</surname>
</string-name>, and <string-name>
<given-names>K. C.</given-names>
<surname>Wanseck</surname>
</string-name>, et al. <year>2015</year>
<article-title>Expression of interferon‐gamma receptor genes in peripheral blood mononuclear cells is associated with rheumatoid arthritis and its radiographic severity in African Americans</article-title>. <source/>Arthritis Rheumatol. (Hoboken, NJ). <volume>67</volume>:<fpage>1165</fpage>–<lpage>1170</lpage>.<pub-id pub-id-type="pmid">25708927</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0031">
<label>31</label>
<mixed-citation id="cam41256-cit-0031" publication-type="journal">
<string-name>
<surname>Takagawa</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Nakamura</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kumagai</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Nagashima</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Goshima</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Saito</surname>
</string-name>. <year>2013</year>
<article-title>Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis</article-title>. <source/>BMC Musculoskelet. Disord.
<volume>14</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">23343469</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0032">
<label>32</label>
<mixed-citation id="cam41256-cit-0032" publication-type="journal">
<string-name>
<surname>Park</surname>, <given-names>J.‐S.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Yaster</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Guan</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ji‐Tian</surname>
</string-name>, <string-name>
<given-names>M.‐H.</given-names>
<surname>Shih</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Guan</surname>
</string-name>, <string-name>
<given-names>Srinivasa. N.</given-names>
<surname>Raja</surname>
</string-name>, <string-name>
<given-names>Y.‐X.</given-names>
<surname>Tao</surname>
</string-name>, et al. <year>2008</year>
<article-title>Role of spinal cord alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors in complete Freund's adjuvant‐induced inflammatory pain</article-title>. <source/>Mol. Pain.
<volume>4</volume>:<fpage>67</fpage>.<pub-id pub-id-type="pmid">19116032</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0033">
<label>33</label>
<mixed-citation id="cam41256-cit-0033" publication-type="journal">
<string-name>
<surname>Vikman</surname>, <given-names>K. S.</given-names>
</string-name>, <string-name>
<given-names>R. H.</given-names>
<surname>Hill</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Backstrom</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Robertson</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Kristensson</surname>
</string-name>. <year>2003</year>
<article-title>Interferon‐gamma induces characteristics of central sensitization in spinal dorsal horn neurons in vitro</article-title>. <source/>Pain
<volume>106</volume>:<fpage>241</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">14659507</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0034">
<label>34</label>
<mixed-citation id="cam41256-cit-0034" publication-type="journal">
<string-name>
<surname>Choi</surname>, <given-names>J. I.</given-names>
</string-name>, <string-name>
<given-names>C. I.</given-names>
<surname>Svensson</surname>
</string-name>, <string-name>
<given-names>F. J.</given-names>
<surname>Koehrn</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Bhuskute</surname>
</string-name>, and <string-name>
<given-names>L. S.</given-names>
<surname>Sorkin</surname>
</string-name>. <year>2010</year>
<article-title>Peripheral inflammation induces tumor necrosis factor dependent AMPA receptor trafficking and Akt phosphorylation in spinal cord in addition to pain behavior</article-title>. <source/>Pain
<volume>149</volume>:<fpage>243</fpage>–<lpage>253</lpage>.<pub-id pub-id-type="pmid">20202754</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0035">
<label>35</label>
<mixed-citation id="cam41256-cit-0035" publication-type="journal">
<string-name>
<surname>Liang</surname>, <given-names>Y. J.</given-names>
</string-name>, <string-name>
<given-names>D. F.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Stumm</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Hollt</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Koch</surname>
</string-name>. <year>2008</year>
<article-title>Membrane glycoprotein M6A promotes mu‐opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway</article-title>. <source/>Cell Res.
<volume>18</volume>:<fpage>768</fpage>–<lpage>779</lpage>.<pub-id pub-id-type="pmid">18574501</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0036">
<label>36</label>
<mixed-citation id="cam41256-cit-0036" publication-type="journal">
<string-name>
<surname>Myers</surname>, <given-names>B.</given-names>
</string-name>, and <string-name>
<given-names>Meerveld. B.</given-names>
<surname>Greenwood‐Van</surname>
</string-name>. <year>2010</year>
<article-title>Divergent effects of amygdala glucocorticoid and mineralocorticoid receptors in the regulation of visceral and somatic pain</article-title>. <source/>Am. J. Physiol. Gastrointest. Liver Physiol.
<volume>298</volume>:<fpage>G295</fpage>–<lpage>G303</lpage>.<pub-id pub-id-type="pmid">19875699</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0037">
<label>37</label>
<mixed-citation id="cam41256-cit-0037" publication-type="journal">
<string-name>
<surname>Lentjes</surname>, <given-names>E. G.</given-names>
</string-name>, <string-name>
<given-names>E. N.</given-names>
<surname>Griep</surname>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Boersma</surname>
</string-name>, <string-name>
<given-names>F. P.</given-names>
<surname>Romijn</surname>
</string-name>, and <string-name>
<given-names>E. R.</given-names>
<surname>de Kloet</surname>
</string-name>. <year>1997</year>
<article-title>Glucocorticoid receptors, fibromyalgia and low back pain</article-title>. <source/>Psychoneuroendocrinology
<volume>22</volume>:<fpage>603</fpage>–<lpage>614</lpage>.<pub-id pub-id-type="pmid">9483705</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0038">
<label>38</label>
<mixed-citation id="cam41256-cit-0038" publication-type="journal">
<string-name>
<surname>Fenner</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Scannell</surname>
</string-name>, and <string-name>
<given-names>J. H.</given-names>
<surname>Prehn</surname>
</string-name>. <year>2009</year>
<article-title>Identification of polyubiquitin binding proteins involved in NF‐kappaB signaling using protein arrays</article-title>. <source/>Biochem. Biophys. Acta.
<volume>1794</volume>:<fpage>1010</fpage>–<lpage>1016</lpage>.<pub-id pub-id-type="pmid">19285159</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0039">
<label>39</label>
<mixed-citation id="cam41256-cit-0039" publication-type="journal">
<string-name>
<surname>Qi</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>Gervais</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>DeCaprio</surname>
</string-name>, <string-name>
<given-names>J. R.</given-names>
<surname>Challis</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ohh</surname>
</string-name>. <year>2004</year>
<article-title>Molecular cloning and characterization of the von Hippel‐Lindau‐like protein</article-title>. <source/>Mol. Cancer Res.
<volume>2</volume>:<fpage>43</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">14757845</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0040">
<label>40</label>
<mixed-citation id="cam41256-cit-0040" publication-type="journal">
<string-name>
<surname>Laroche</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Coste</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Medkour</surname>
</string-name>, <string-name>
<given-names>P. H.</given-names>
<surname>Cottu</surname>
</string-name>, <string-name>
<given-names>J.‐Y.</given-names>
<surname>Pierga</surname>
</string-name>, <string-name>
<given-names>J.‐P.</given-names>
<surname>Lotz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Beerblock</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Tournigand</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Declèves</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>de Cremoux</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Bouhassira</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Perrot</surname>
</string-name>, et al. <year>2014</year>
<article-title>Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study</article-title>. <source/>J. Pain.
<volume>15</volume>:<fpage>293</fpage>–<lpage>303</lpage>.<pub-id pub-id-type="pmid">24365325</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0041">
<label>41</label>
<mixed-citation id="cam41256-cit-0041" publication-type="journal">
<string-name>
<surname>Fontein</surname>, <given-names>Duveken. B. Y.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Houtsma</surname>
</string-name>, <string-name>
<given-names>Johan. W. R.</given-names>
<surname>Nortier</surname>
</string-name>, <string-name>
<given-names>Renee. F.</given-names>
<surname>Baak‐Pablo</surname>
</string-name>, <string-name>
<given-names>E. M.‐K.</given-names>
<surname>Kranenbarg</surname>
</string-name>, <string-name>
<given-names>Tahar. R. J. H. M.</given-names>
<surname>van der Straaten</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Putter</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Seynaeve</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Gelderblom</surname>
</string-name>, <string-name>
<given-names>Cornelis. J. H.</given-names>
<surname>van de Velde</surname>
</string-name>, <string-name>
<given-names>H.‐J.</given-names>
<surname>Guchelaar</surname>
</string-name>, et al. <year>2014</year>
<article-title>Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial</article-title>. <source/>Breast Cancer Res. Treat.
<volume>144</volume>:<fpage>599</fpage>–<lpage>606</lpage>.<pub-id pub-id-type="pmid">24590773</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0042">
<label>42</label>
<mixed-citation id="cam41256-cit-0042" publication-type="journal">
<string-name>
<surname>Gervasini</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Jara</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Olier</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Romero</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Martinez</surname>
</string-name>, and <string-name>
<given-names>J. A.</given-names>
<surname>Carrillo</surname>
</string-name>. <year>2017</year>
<article-title>Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients</article-title>. <source/>Br. J. Clin. Pharmacol.
<volume>83</volume>:<fpage>562</fpage>–<lpage>571</lpage>.<pub-id pub-id-type="pmid">27747906</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0043">
<label>43</label>
<mixed-citation id="cam41256-cit-0043" publication-type="journal">
<string-name>
<surname>Hertz</surname>, <given-names>D. L.</given-names>
</string-name>, <string-name>
<given-names>N. L.</given-names>
<surname>Henry</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Rae</surname>
</string-name>. <year>2017</year>
<article-title>Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients</article-title>. <source/>Pharmacogenomics
<volume>18</volume>:<fpage>481</fpage>–<lpage>499</lpage>.<pub-id pub-id-type="pmid">28346074</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0044">
<label>44</label>
<mixed-citation id="cam41256-cit-0044" publication-type="journal">
<string-name>
<surname>Weis‐Klemm</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Alexander</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Pap</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Schützle</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Reyer</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Franz</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Aicher</surname>
</string-name>, et al. <year>2004</year>
<article-title>Synovial fibroblasts from rheumatoid arthritis patients differ in their regulation of IL‐16 gene activity in comparison to osteoarthritis fibroblasts</article-title>. <source/>Cell. Physiol. Biochem.
<volume>14</volume>(<issue>4–6</issue>):<fpage>293</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">15319533</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0045">
<label>45</label>
<mixed-citation id="cam41256-cit-0045" publication-type="journal">
<string-name>
<surname>Blaschke</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Schulz</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Schwarz</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Blaschke</surname>
</string-name>, <string-name>
<given-names>G. A.</given-names>
<surname>Muller</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Reuss‐Borst</surname>
</string-name>. <year>2001</year>
<article-title>Interleukin 16 expression in relation to disease activity in rheumatoid arthritis</article-title>. <source/>J. Rheumatol.
<volume>28</volume>:<fpage>12</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">11196512</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0046">
<label>46</label>
<mixed-citation id="cam41256-cit-0046" publication-type="journal">
<string-name>
<surname>Kageyama</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ozeki</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Suzuki</surname>
</string-name>, et al. <year>2000</year>
<article-title>Interleukin‐16 in synovial fluids from cases of various types of arthritis</article-title>. <source/>Joint, Bone, Spine
<volume>67</volume>:<fpage>188</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">10875316</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0047">
<label>47</label>
<mixed-citation id="cam41256-cit-0047" publication-type="journal">
<string-name>
<surname>Lard</surname>, <given-names>L. R.</given-names>
</string-name>, <string-name>
<given-names>B. O.</given-names>
<surname>Roep</surname>
</string-name>, <string-name>
<given-names>R. E.</given-names>
<surname>Toes</surname>
</string-name>, and <string-name>
<given-names>T. W.</given-names>
<surname>Huizinga</surname>
</string-name>. <year>2004</year>
<article-title>Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis</article-title>. <source/>J. Rheumatol.
<volume>31</volume>:<fpage>35</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">14705216</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0048">
<label>48</label>
<mixed-citation id="cam41256-cit-0048" publication-type="journal">
<string-name>
<surname>Luo</surname>, <given-names>S.‐X.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>X.‐H.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>J.‐J.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>G.‐H.</given-names>
<surname>Long</surname>
</string-name>, <string-name>
<given-names>G.‐F.</given-names>
<surname>Dong</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wei</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Deng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>J.‐M.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Qin</surname>
</string-name>, et al. <year>2015</year>
<article-title>Genetic polymorphisms of interleukin‐16 and risk of knee osteoarthritis</article-title>. <source/>PLoS ONE
<volume>10</volume>:<fpage>e0123442</fpage>.<pub-id pub-id-type="pmid">25954818</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0049">
<label>49</label>
<mixed-citation id="cam41256-cit-0049" publication-type="journal">
<string-name>
<surname>McFadden</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Morgan</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Rahangdale</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Green</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Yamasaki</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Center</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Cruikshank</surname>
</string-name>, et al. <year>2007</year>
<article-title>Preferential migration of T regulatory cells induced by IL‐16</article-title>. <source/>J. Immunol. (Baltimore, Md: 1950)<volume>179</volume>:<fpage>6439</fpage>–<lpage>6445</lpage>.<pub-id pub-id-type="pmid">17982032</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0050">
<label>50</label>
<mixed-citation id="cam41256-cit-0050" publication-type="journal">
<string-name>
<surname>Wilson</surname>, <given-names>K. C.</given-names>
</string-name>, <string-name>
<given-names>D. M.</given-names>
<surname>Center</surname>
</string-name>, and <string-name>
<given-names>W. W.</given-names>
<surname>Cruikshank</surname>
</string-name>. <year>2004</year>
<article-title>The effect of interleukin‐16 and its precursor on T lymphocyte activation and growth</article-title>. <source/>Growth Factors (Chur, Switzerland) <volume>22</volume>:<fpage>97</fpage>–<lpage>104</lpage>.<pub-id pub-id-type="pmid">15253385</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0051">
<label>51</label>
<mixed-citation id="cam41256-cit-0051" publication-type="journal">
<string-name>
<surname>Ribardo</surname>, <given-names>D. A.</given-names>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Peterson</surname>
</string-name>, and <string-name>
<given-names>A. K.</given-names>
<surname>Chopra</surname>
</string-name>. <year>2002</year>
<article-title>Phospholipase A2‐activating protein–an important regulatory molecule in modulating cyclooxygenase‐2 and tumor necrosis factor production during inflammation</article-title>. <source/>Indian J. Exp. Biol.
<volume>40</volume>:<fpage>129</fpage>–<lpage>138</lpage>.<pub-id pub-id-type="pmid">12622174</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0052">
<label>52</label>
<mixed-citation id="cam41256-cit-0052" publication-type="journal">
<string-name>
<surname>Duarte‐Pereira</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Paiva</surname>
</string-name>, <string-name>
<given-names>V. L.</given-names>
<surname>Costa</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Ramalho‐Carvalho</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Savva‐Bordalo</surname>
</string-name>, <string-name>
<given-names>Â.</given-names>
<surname>Rodrigues</surname>
</string-name>, <string-name>
<given-names>F. R.</given-names>
<surname>Ribeiro</surname>
</string-name>, <string-name>
<given-names>Vitor. M.</given-names>
<surname>Silva</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Oliveira</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Henrique</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Jerónimo</surname>
</string-name>, et al. <year>2011</year>
<article-title>Prognostic value of opioid binding protein/cell adhesion molecule‐like promoter methylation in bladder carcinoma</article-title>. <source/>Eur. J. Cancer
<volume>47</volume>:<fpage>1106</fpage>–<lpage>1114</lpage>.<pub-id pub-id-type="pmid">21273058</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0053">
<label>53</label>
<mixed-citation id="cam41256-cit-0053" publication-type="journal">
<string-name>
<surname>Cui</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ying</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>van Hasselt</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Ng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Jun</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Johng. S.</given-names>
<surname>Rhim</surname>
</string-name>, <string-name>
<given-names>S. Y.</given-names>
<surname>Rha</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Loyo</surname>
</string-name>, <string-name>
<given-names>Anthony. T. C.</given-names>
<surname>Chan</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Srivastava</surname>
</string-name>, <string-name>
<given-names>George. S. W.</given-names>
<surname>Tsao</surname>
</string-name>, <string-name>
<given-names>Grant. C.</given-names>
<surname>Sellar</surname>
</string-name>, <string-name>
<given-names>Joseph. J. Y.</given-names>
<surname>Sung</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Sidransky</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Tao</surname>
</string-name>, et al. <year>2008</year>
<article-title>OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation</article-title>. <source/>PLoS ONE
<volume>3</volume>:<fpage>e2990</fpage>.<pub-id pub-id-type="pmid">18714356</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0054">
<label>54</label>
<mixed-citation id="cam41256-cit-0054" publication-type="journal">
<string-name>
<surname>Zhou</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Tao</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>Cao</surname>
</string-name>. <year>2014</year>
<article-title>Detection of circulating methylated opioid binding protein/cell adhesion molecule‐like gene as a biomarker for ovarian carcinoma</article-title>. <source/>Clin. Lab.
<volume>60</volume>:<fpage>759</fpage>–<lpage>765</lpage>.<pub-id pub-id-type="pmid">24839818</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0055">
<label>55</label>
<mixed-citation id="cam41256-cit-0055" publication-type="journal">
<string-name>
<surname>Yi</surname>, <given-names>C. H.</given-names>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>W. W.</given-names>
<surname>West</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Hollingsworth</surname>
</string-name>. <year>2007</year>
<article-title>Loss of fibulin‐2 expression is associated with breast cancer progression</article-title>. <source/>Am. J. Pathol.
<volume>170</volume>:<fpage>1535</fpage>–<lpage>1545</lpage>.<pub-id pub-id-type="pmid">17456760</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0056">
<label>56</label>
<mixed-citation id="cam41256-cit-0056" publication-type="journal">
<string-name>
<surname>Xiong</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>B. M.</given-names>
<surname>Evers</surname>
</string-name>, <string-name>
<given-names>B. P.</given-names>
<surname>Zhou</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Xu</surname>
</string-name>. <year>2012</year>
<article-title>RORalpha suppresses breast tumor invasion by inducing SEMA3F expression</article-title>. <source/>Can. Res.
<volume>72</volume>:<fpage>1728</fpage>–<lpage>1739</lpage>.</mixed-citation>
</ref>
<ref id="cam41256-bib-0057">
<label>57</label>
<mixed-citation id="cam41256-cit-0057" publication-type="journal">
<string-name>
<surname>Sarachana</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>R. C.</given-names>
<surname>Wu</surname>
</string-name>, and <string-name>
<given-names>V. W.</given-names>
<surname>Hu</surname>
</string-name>. <year>2011</year>
<article-title>Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e17116</fpage>.<pub-id pub-id-type="pmid">21359227</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0058">
<label>58</label>
<mixed-citation id="cam41256-cit-0058" publication-type="journal">
<string-name>
<surname>Odawara</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Iwasaki</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Horiguchi</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Rokutanda</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Hirooka</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Miyazaki</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Koibuchi</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Shimokawa</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Iino</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Takeyoshi</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Koibuchi</surname>
</string-name>, et al. <year>2009</year>
<article-title>Activation of aromatase expression by retinoic acid receptor‐related orphan receptor (ROR) alpha in breast cancer cells: identification of a novel ROR response element</article-title>. <source/>The Journal of biological chemistry.
<volume>284</volume>:<fpage>17711</fpage>–<lpage>17719</lpage>.<pub-id pub-id-type="pmid">19439415</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0059">
<label>59</label>
<mixed-citation id="cam41256-cit-0059" publication-type="journal">
<string-name>
<surname>Xiao</surname>, <given-names>G. G.</given-names>
</string-name>, <string-name>
<given-names>B. S.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Somlo</surname>
</string-name>, et al. <year>2008</year>
<article-title>Identification of F‐box/LLR‐repeated protein 17 as potential useful biomarker for breast cancer therapy</article-title>. <source/>Cancer Genomics Proteomics
<volume>5</volume>(<issue>3–4</issue>):<fpage>151</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">18820369</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0060">
<label>60</label>
<mixed-citation id="cam41256-cit-0060" publication-type="journal">
<string-name>
<surname>Stanford</surname>, <given-names>Stephanie. M.</given-names>
</string-name>, <string-name>
<given-names>German. R.</given-names>
<surname>Aleman</surname>
</string-name>, <string-name>
<given-names>B. B.</given-names>
<surname>Muench</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Sacchetti</surname>
</string-name>, <string-name>
<given-names>William. B.</given-names>
<surname>Kiosses</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Sharma</surname>
</string-name>, <string-name>
<given-names>Michael. F.</given-names>
<surname>Maestre</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Bottini</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Mustelin</surname>
</string-name>, <string-name>
<given-names>David. L.</given-names>
<surname>Boyle</surname>
</string-name>, <string-name>
<given-names>Gary. S.</given-names>
<surname>Firestein</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Bottini</surname>
</string-name>, et al. <year>2016</year>
<article-title>TGFbeta responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness</article-title>. <source/>Ann. Rheum. Dis.
<volume>75</volume>:<fpage>295</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="pmid">25378349</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0061">
<label>61</label>
<mixed-citation id="cam41256-cit-0061" publication-type="journal">
<string-name>
<surname>Sun</surname>, <given-names>P. H.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ye</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Mason</surname>
</string-name>, and <string-name>
<given-names>W. G.</given-names>
<surname>Jiang</surname>
</string-name>. <year>2013</year>
<article-title>Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer</article-title>. <source/>J. Cancer Res. Clin. Oncol.
<volume>139</volume>:<fpage>1129</fpage>–<lpage>1139</lpage>.<pub-id pub-id-type="pmid">23552869</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0062">
<label>62</label>
<mixed-citation id="cam41256-cit-0062" publication-type="journal">
<string-name>
<surname>Lane</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>T. A.</given-names>
<surname>Martin</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>McGuigan</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Mason</surname>
</string-name>, and <string-name>
<given-names>W. G.</given-names>
<surname>Jiang</surname>
</string-name>. <year>2010</year>
<article-title>The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy</article-title>. <source/>J. Exp. Ther. Oncol.
<volume>8</volume>:<fpage>203</fpage>–<lpage>210</lpage>.<pub-id pub-id-type="pmid">20734919</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0063">
<label>63</label>
<mixed-citation id="cam41256-cit-0063" publication-type="journal">
<string-name>
<surname>Cano‐Soldado</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Molina‐Arcas</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Algueró</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Larráyoz</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Pilar Lostao</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Grandas</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Javier Casado</surname>
</string-name>. <year>2008</year>
<article-title>Compensatory effects of the human nucleoside transporters on the response to nucleoside‐derived drugs in breast cancer MCF7 cells</article-title>. <source/>Biochem. Pharmacol.
<volume>75</volume>:<fpage>639</fpage>–<lpage>648</lpage>.<pub-id pub-id-type="pmid">18053967</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0064">
<label>64</label>
<mixed-citation id="cam41256-cit-0064" publication-type="journal">
<string-name>
<surname>Okubo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kimura</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Fujita</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Mochizuki</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Niki</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Enomoto</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Suda</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Toyama</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Okada</surname>
</string-name>, et al. <year>2011</year>
<article-title>Semaphorin 3A is expressed in human osteoarthritic cartilage and antagonizes vascular endothelial growth factor 165‐promoted chondrocyte migration: an implication for chondrocyte cloning</article-title>. <source/>Arthritis Rheum.
<volume>63</volume>:<fpage>3000</fpage>–<lpage>3009</lpage>.<pub-id pub-id-type="pmid">21953086</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0065">
<label>65</label>
<mixed-citation id="cam41256-cit-0065" publication-type="journal">
<string-name>
<surname>Hjorten</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Hansen</surname>
</string-name>, <string-name>
<given-names>Robert. A.</given-names>
<surname>Underwood</surname>
</string-name>, <string-name>
<given-names>Helena. E.</given-names>
<surname>Telfer</surname>
</string-name>, <string-name>
<given-names>Russell. J.</given-names>
<surname>Fernandes</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Krakow</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Sebald</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wachsmann‐Hogiu</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Bruckner</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Jacquet</surname>
</string-name>, <string-name>
<given-names>William. J.</given-names>
<surname>Landis</surname>
</string-name>, <string-name>
<given-names>Peter. H.</given-names>
<surname>Byers</surname>
</string-name>, and <string-name>
<given-names>James. M.</given-names>
<surname>Pace</surname>
</string-name>. <year>2007</year>
<article-title>Type XXVII collagen at the transition of cartilage to bone during skeletogenesis</article-title>. <source/>Bone
<volume>41</volume>:<fpage>535</fpage>–<lpage>542</lpage>.<pub-id pub-id-type="pmid">17693149</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0066">
<label>66</label>
<mixed-citation id="cam41256-cit-0066" publication-type="journal">
<string-name>
<surname>Saunders</surname>, <given-names>Colleen. J.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>van der Merwe</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Posthumus</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Cook</surname>
</string-name>, <string-name>
<given-names>Christopher. J.</given-names>
<surname>Handley</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Collins</surname>
</string-name>, <string-name>
<given-names>Alison. V.</given-names>
<surname>September</surname>
</string-name>, et al. <year>2013</year>
<article-title>Investigation of variants within the COL27A1 and TNC genes and Achilles tendinopathy in two populations</article-title>. <source/>J. Orthop. Res.
<volume>31</volume>:<fpage>632</fpage>–<lpage>637</lpage>.<pub-id pub-id-type="pmid">23192621</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0067">
<label>67</label>
<mixed-citation id="cam41256-cit-0067" publication-type="journal">
<string-name>
<surname>Syx</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Malfait</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Van Laer</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Hellemans</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Hermanns‐Lê</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Willaert</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Benmansour</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>De Paepe</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Verloes</surname>
</string-name>. <year>2010</year>
<article-title>The RIN2 syndrome: a new autosomal recessive connective tissue disorder caused by deficiency of Ras and Rab interactor 2 (RIN2)</article-title>. <source/>Hum. Genet.
<volume>128</volume>:<fpage>79</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">20424861</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0068">
<label>68</label>
<mixed-citation id="cam41256-cit-0068" publication-type="journal">
<string-name>
<surname>Dong</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Han</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Zylka</surname>
</string-name>, <string-name>
<given-names>M. I.</given-names>
<surname>Simon</surname>
</string-name>, and <string-name>
<given-names>D. J.</given-names>
<surname>Anderson</surname>
</string-name>. <year>2001</year>
<article-title>A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons</article-title>. <source/>Cell
<volume>106</volume>:<fpage>619</fpage>–<lpage>632</lpage>.<pub-id pub-id-type="pmid">11551509</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0069">
<label>69</label>
<mixed-citation id="cam41256-cit-0069" publication-type="journal">
<string-name>
<surname>Shozu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Sebastian</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Takayama</surname>
</string-name>, <string-name>
<given-names>W.‐T.</given-names>
<surname>Hsu</surname>
</string-name>, <string-name>
<given-names>Roger. A.</given-names>
<surname>Schultz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Neely</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Bryant</surname>
</string-name>, and <string-name>
<given-names>Serdar. E.</given-names>
<surname>Bulun</surname>
</string-name>. <year>2003</year>
<article-title>Estrogen excess associated with novel gain‐of‐function mutations affecting the aromatase gene</article-title>. <source/>N. Engl. J. Med.
<volume>348</volume>:<fpage>1855</fpage>–<lpage>1865</lpage>.<pub-id pub-id-type="pmid">12736278</pub-id></mixed-citation>
</ref>
<ref id="cam41256-bib-0070">
<label>70</label>
<mixed-citation id="cam41256-cit-0070" publication-type="journal">
<string-name>
<surname>Demura</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Martin</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Shozu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Sebastian</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Takayama</surname>
</string-name>, <string-name>
<given-names>W.‐T.</given-names>
<surname>Hsu</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Schultz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Neely</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Bryant</surname>
</string-name>, <string-name>
<given-names>B. B.</given-names>
<surname>Mendonca</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Hanaki</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kanzaki</surname>
</string-name>, <string-name>
<given-names>D. B.</given-names>
<surname>Rhoads</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Misra</surname>
</string-name>, <string-name>
<given-names>S. E.</given-names>
<surname>Bulun</surname>
</string-name>. <year>2007</year>
<article-title>Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene</article-title>. <source/>Hum. Mol. Genet.
<volume>16</volume>:<fpage>2529</fpage>–<lpage>2541</lpage>.<pub-id pub-id-type="pmid">17584767</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>